700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Research Article Open Access
Oral controlled release drug delivery systems are one of the promising systems for prolonged duration of action for chronic diseases like hypertension, diabetes etc. Drugs with absorption window in upper GIT (gastro intestinal tract) require special attention for effective therapy. Gastric floating drug delivery systems (GFDDS) are one such suitable delivery system. In our present investigation we attempted to utilize modified pulsincap technique to develop GFDDS of propranolol HCl using PEO WSR 303 polymer. Modified pulsincap technique involve exposing the capsule body to formaldehyde vapors which results in hardening of the shell. The drug- polymer- excipient mixture was filled into the hardened body and covered with untreated cap. All the formulations were evaluated for residual formaldehyde estimation, weight variation, drug content, in-vitro buoyancy, drug release pattern, compatibility studies etc. The formulations F1-4 with drug-polymer ratio 1:0.75 of 1 hr formaldehyde vapour exposure and F2-3 with drug: polymer ratio 1:0.5 of 2 hrs formaldehyde vapour exposure were considered as the optimized formulations as they released 99.99% and 100.00% of the drug in 12 hrs respectively with sufficient buoyancy characteristics. Promising results concluded that the modified pulsincap technique can be successfully used for the development of GFDDS of propranolol HCl using PEO WSR 303.
To read the full article Peer-reviewed Article PDF
Author(s): GSN Koteswara Rao, KV Ramana Murthy, Aayisha Begum, B Roja Rani, Ch Ragha Naveen, B Raj Kumar, P Uma Devi
Formaldehyde, floating capsules, modified pulsincap, propranolol HCl, PEO WSR 303, Liver Inflammation